Morgan Stanley analyst David Bailey initiated coverage of Fisher & Paykel Healthcare with an Equal Weight rating and NZ$36.30 price target A strong EPS outlook over the next three years is underpinned by new applications growth in the Hospital segment and recent obstructive sleep apnea mask launches, but the introduction of U.S. tariffs presents potential delays to margin targets, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF:
- Fisher & Paykel Healthcare Unveils F&P Nova Nasal Mask in New Zealand and Australia
- Fisher & Paykel Healthcare Announces Share Transfer to VP
- Fisher & Paykel Healthcare Expands Auckland Campus with New Building
- Hyperion Asset Management Reduces Stake in Fisher & Paykel Healthcare
- Mitsubishi UFJ Reduces Stake in Fisher & Paykel Healthcare